Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model

  • Authors:
    • Wei Yang
    • Yu-Hua Chen
    • Hao Liu
    • Hong-Dang Qu
  • View Affiliations

  • Published online on: September 28, 2015     https://doi.org/10.3892/ijmm.2015.2356
  • Pages: 1369-1376
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Parkinson's disease (PD) is second only to Alzheimer's disease as the most common and debilitating age-associated neurodegenerative disorder. Currently, no therapy has been shown to unequivocally retard or arrest the progression of the disease. The aim of the present study was to investigate the protective effect of piperine on the 1-methyl-4-phenyl-1,2,3,6‑tetrahydropyridine (MPTP)-induced Parkinson's mouse model. For MPTP treatment, the animals received repeated intraperitoneal injections (i.p.) of MPTP (30 mg/kg) solution for 7 days. Piperine (10 mg/kg) was administered orally for 15 days including 8 days of pretreatment. Motor behavior analysis was conducted with the rotarod test. The Morris water maze (MWM) was used to assess the cognitive learning ability of the mice. A histological examination was subsequently conducted. The results ddemonstrate that piperine treatment attenuated MPTP-induced deficits in motor coordination and cognitive functioning. Piperine also prevented MPTP-induced decreases in the number of tyrosine hydroxylase-positive cells in the substantia nigra. Additionally, piperine reduced the number of activated microglia, expression of cytokine IL-1β, and oxidative stress following MPTP treatment. An anti-apoptotic property of piperine was identified by maintaining the balance of Bcl-2/Bax. In conclusion, the results show that piperine exerts a protective effect on dopaminergic neurons via antioxidant, anti-apoptotic, and anti-inflammatory mechanisms in an MPTP-induced mouse model of PD. Thus, piperine is a potential therapeutic treatment for PD.

References

1 

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, et al: Priorities in Parkinson's disease research. Nat Rev Drug Discov. 10:377–393. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Noelker C, Bacher M, Gocke P, Wei X, Klockgether T, Du Y and Dodel R: The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity. Neurosci Lett. 383:39–43. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Jankovic J: Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 79:368–376. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Engler H, Doenlen R, Riether C, Engler A, Niemi MB, Besedovsky HO, del Rey A, Pacheco-López G, Feldon J and Schedlowski M: Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain Behav Immun. 23:518–526. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF and Hadjigeorgiou GM: The interplay between environmental and genetic factors in Parkinson's disease susceptibility: The evidence for pesticides. Toxicology. 307:17–23. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Hirsch EC, Hunot S, Faucheux B, Agid Y, Mizuno Y, Mochizuki H, Tatton WG, Tatton N and Olanow WC: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord. 14:383–385. 1999. View Article : Google Scholar : PubMed/NCBI

7 

Miller RL, James-Kracke M, Sun GY and Sun AY: Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res. 34:55–65. 2009. View Article : Google Scholar

8 

Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, et al: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 25:302–305. 2000. View Article : Google Scholar : PubMed/NCBI

9 

Dugan LL, Tian L, Quick KL, Hardt JI, Karimi M, Brown C, Loftin S, Flores H, Moerlein SM, Polich J, et al: Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates. Ann Neurol. 76:393–402. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Cassarino DS, Parks JK, Parker WD Jr and Bennett JP Jr: The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta. 1453:49–62. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Lotharius J, Dugan LL and O'Malley KL: Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci. 19:1284–1293. 1999.PubMed/NCBI

12 

Lee CS, Han ES, Jang YY, Han JH, Ha HW and Kim DE: Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J Neurochem. 75:521–531. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Lee CS, Park SY, Ko HH, Song JH, Shin YK and Han ES: Inhibition of MPP+-induced mitochondrial damage and cell death by trifluoperazine and W-7 in PC12 cells. Neurochem Int. 46:169–178. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Rojas P and Rios C: Increased striatal lipid peroxidation after intracerebroventricular MPP+ administration to mice. Pharmacol Toxicol. 72:364–368. 1993. View Article : Google Scholar : PubMed/NCBI

15 

Abdel-Salam OM: Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 7:321–342. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Wattanathorn J, Chonpathompikunlert P, Muchimapura S, Priprem A and Tankamnerdthai O: Piperine, the potential functional food for mood and cognitive disorders. Food Chem Toxicol. 46:3106–3110. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Shrivastava P, Vaibhav K, Tabassum R, Khan A, Ishrat T, Khan MM, Ahmad A and Islam F, Safhi MM and Islam F: Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model. J Nutr Biochem. 24:680–687. 2013. View Article : Google Scholar

18 

Vijayakumar RS1, Surya D and Nalini N: Antioxidant efficacy of black pepper (Piper nigrum L.) and piperine in rats with high fat diet induced oxidative stress. Redox Rep. 9:105–110. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Bajad S, Bedi KL, Singla AK and Johri RK: Antidiarrhoeal activity of piperine in mice. Planta Med. 67:284–287. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Bai YF and Xu H: Protective action of piperine against experimental gastric ulcer. Acta Pharmacol Sin. 21:357–359. 2000.

21 

Selvendiran K, Prince Vijeya Singh J and Sakthisekaran D: In vivo effect of piperine on serum and tissue glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Pulm Pharmacol Ther. 19:107–111. 2006. View Article : Google Scholar

22 

Gupta SK, Bansal P, Bhardwaj RK and Velpandian T: Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs. nimesulide and piperine combination. Pharmacol Res. 41:657–662. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Atal CK, Dubey RK and Singh J: Biochemical basis of enhanced drug bioavailability by piperine: Evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther. 232:258–262. 1985.PubMed/NCBI

24 

Hu Y, Liao HB, Liu P, Guo DH and Wang YY: Antidepressant effects of piperine and its neuroprotective mechanism in rats. Zhong Xi Yi Jie He Xue Bao. 7:667–670. 2009.In Chinese. View Article : Google Scholar : PubMed/NCBI

25 

Chonpathompikunlert P, Wattanathorn J and Muchimapura S: Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. Food Chem Toxicol. 48:798–802. 2010. View Article : Google Scholar

26 

Lee CS, Han ES and Kim YK: Piperine inhibition of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells. Eur J Pharmacol. 537:37–44. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Rozas G, López-Martín E, Guerra MJ and Labandeira-García JL: The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods. 83:165–175. 1998. View Article : Google Scholar : PubMed/NCBI

28 

Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, During M, Kholodilov N and Burke RE: Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol. 70:110–120. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Kim SR, Kareva T, Yarygina O, Kholodilov N and Burke RE: AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther. 20:275–286. 2012. View Article : Google Scholar :

30 

Kim SR, Chung ES, Bok E, Baik HH, Chung YC, Won SY, Joe E, Kim TH, Kim SS, Jin MY, et al: Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res. 88:1537–1548. 2010.

31 

Burnette WN: 'Western blotting': Electrophoretic transfer of proteins from sodium dodecyl sulfate - polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 112:195–203. 1981. View Article : Google Scholar : PubMed/NCBI

32 

Casani S, Gómez-Pastor R, Matallana E and Paricio N: Antioxidant compound supplementation prevents oxidative damage in a Drosophila model of Parkinson's disease. Free Radic Biol Med. 61:151–160. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Block ML and Hong JS: Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol. 76:77–98. 2005. View Article : Google Scholar : PubMed/NCBI

34 

Wang T, Zhang W, Pei Z, Block M, Wilson B, Reece JM, Miller DS and Hong JS: Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor. FASEB J. 20:906–915. 2006. View Article : Google Scholar : PubMed/NCBI

35 

Baillet A, Chanteperdrix V, Trocmé C, Casez P, Garrel C and Besson G: The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res. 35:1530–1537. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Carvalho AN, Marques C, Rodrigues E, Henderson CJ, Wolf CR, Pereira P and Gama MJ: Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice. Mol Neurobiol. 47:662–672. 2013. View Article : Google Scholar

37 

Jakowec MW and Petzinger GM: 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med. 54:497–513. 2004.PubMed/NCBI

38 

Sundström E, Fredriksson A and Archer T: Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 528:181–188. 1990. View Article : Google Scholar : PubMed/NCBI

39 

Kurz MJ, Pothakos K, Jamaluddin S, Scott-Pandorf M, Arellano C and Lau YS: A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. Neurosci Lett. 429:39–42. 2007. View Article : Google Scholar : PubMed/NCBI

40 

Petroske E, Meredith GE, Callen S, Totterdell S and Lau YS: Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 106:589–601. 2001. View Article : Google Scholar : PubMed/NCBI

41 

Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca CI and Prediger RD: Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res. 235:263–272. 2012. View Article : Google Scholar : PubMed/NCBI

42 

Hutter-Saunders JA, Gendelman HE and Mosley RL: Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. J Neuroimmune Pharmacol. 7:279–288. 2012. View Article : Google Scholar :

43 

Whishaw IQ, Li K, Whishaw PA, Gorny B and Metz GA: Use of rotorod as a method for the qualitative analysis of walking in rat. J Vis Exp. 22:10302008.

44 

Emre M, Ford PJ, Bilgic B and Uc EY: Cognitive impairment and dementia in Parkinson's disease: practical issues and management. Mov Disord. 29:663–672. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, et al: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 22:1689–1707. 2007. View Article : Google Scholar : PubMed/NCBI

46 

Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, et al: Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 27:349–356. 2012. View Article : Google Scholar : PubMed/NCBI

47 

Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW and Traynelis SF: Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiol Dis. 67:191–202. 2014. View Article : Google Scholar : PubMed/NCBI

48 

Deleidi M and Gasser T: The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci. 70:4259–4273. 2013. View Article : Google Scholar : PubMed/NCBI

49 

Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR, Zeng YL, Li SN, Huang BX, Lv QK, Wang W, et al: Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson inverted question marks disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation. 12:92015. View Article : Google Scholar

50 

Hirsch EC, Hunot S, Damier P and Faucheux B: Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol. 44(Suppl 1): S115–S120. 1998. View Article : Google Scholar : PubMed/NCBI

51 

Kitamura Y, Itano Y, Kubo T and Nomura Y: Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol. 50:221–224. 1994. View Article : Google Scholar : PubMed/NCBI

52 

Sriram K and O'Callaghan JP: Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol. 2:140–153. 2007. View Article : Google Scholar : PubMed/NCBI

53 

Wang MJ, Huang HY, Chen WF, Chang HF and Kuo JS: Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation. 7:992010. View Article : Google Scholar

54 

Fu SP, Li SN, Wang JF, Li Y, Xie SS, Xue WJ, Liu HM, Huang BX, Lv QK, Lei LC, et al: BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-kappaB activation. Mediators Inflamm. 2014:9834012014. View Article : Google Scholar

55 

Bae GS, Kim MS, Jung WS, Seo SW, Yun SW, Kim SG, Park RK, Kim EC, Song HJ and Park SJ: Inhibition of lipopolysaccharide-induced inflammatory responses by piperine. Eur J Pharmacol. 642:154–162. 2010. View Article : Google Scholar : PubMed/NCBI

56 

Lovell MA, Ehmann WD, Butler SM and Markesbery WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1594–1601. 1995. View Article : Google Scholar : PubMed/NCBI

57 

Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, et al: Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 21:3017–3023. 2001.PubMed/NCBI

58 

Lyras L, Perry RH, Perry EK, Ince PG, Jenner A, Jenner P and Halliwell B: Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem. 71:302–312. 1998. View Article : Google Scholar : PubMed/NCBI

59 

Olanow CW: The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord. 22(Suppl 17): S335–S342. 2007. View Article : Google Scholar

60 

Tatton WG and Olanow CW: Apoptosis in neurodegenerative diseases: The role of mitochondria. Biochim Biophys Acta. 1410:195–213. 1999. View Article : Google Scholar : PubMed/NCBI

61 

Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A and Martinou JC: Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. J Cell Biol. 143:217–224. 1998. View Article : Google Scholar : PubMed/NCBI

62 

Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI

63 

Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2015
Volume 36 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, W., Chen, Y., Liu, H., & Qu, H. (2015). Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model. International Journal of Molecular Medicine, 36, 1369-1376. https://doi.org/10.3892/ijmm.2015.2356
MLA
Yang, W., Chen, Y., Liu, H., Qu, H."Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model". International Journal of Molecular Medicine 36.5 (2015): 1369-1376.
Chicago
Yang, W., Chen, Y., Liu, H., Qu, H."Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model". International Journal of Molecular Medicine 36, no. 5 (2015): 1369-1376. https://doi.org/10.3892/ijmm.2015.2356